# Samrat Pharma (NSE: SAMRATPH) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/SAMRATPH · Pivot · prices to 22 Oct 2026

With a market capitalisation of ₹61 Cr, it ranks 2966th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Chemicals.

Its return on equity was 9.9% in FY25. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹72 Cr (+0.8% year on year) and net profit −₹2 Cr, on a standalone basis. Promoters held 49.09% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Market cap | ₹61 Cr |
| ROE | 9.9% (FY25) |
| ROCE | 14.7% (FY25) |
| Debt to equity | 0.14 |

## Quarterly results (₹ crore, standalone)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹72 Cr | +0.8% | −₹2 Cr | — | −₹6.59 |
| Q3 FY26 | ₹63 Cr | −0.4% | −₹0 Cr | −116.5% | −₹1.49 |
| Q2 FY26 | ₹79 Cr | +12.4% | −₹1 Cr | −122.2% | −₹1.90 |
| Q1 FY26 | ₹76 Cr | −6.4% | −₹0 Cr | −111.1% | −₹0.74 |
| Q4 FY25 | ₹71 Cr | −13.9% | −₹0 Cr | −128.6% | −₹1.29 |
| Q3 FY25 | ₹64 Cr | +3.2% | ₹3 Cr | +717.6% | ₹9.01 |
| Q2 FY25 | ₹70 Cr | −12.0% | ₹3 Cr | — | ₹8.61 |
| Q1 FY25 | ₹81 Cr | +40.6% | ₹2 Cr | +239.3% | ₹6.68 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹286 Cr | ₹7 Cr |
| FY24 | ₹282 Cr | ₹2 Cr |
| FY23 | ₹311 Cr | ₹17 Cr |
| FY22 | ₹222 Cr | ₹17 Cr |
| FY21 | ₹179 Cr | ₹5 Cr |
| FY20 | ₹137 Cr | ₹4 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 49.09%
- Foreign institutions: 3.24%
- Non-institutions: 47.67%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Sunil Health](https://app.pivotnow.in/stock/SUNLOC) | ₹65.00 | ₹67 Cr | 16.6 | — |
| [Royal Sense](https://app.pivotnow.in/stock/ROYAL) | — | ₹59 Cr | — | — |
| [Bacil Pharma](https://app.pivotnow.in/stock/BACPHAR) | — | ₹58 Cr | — | — |
| [Veerhealth Care](https://app.pivotnow.in/stock/VEERHEALTH) | — | ₹58 Cr | — | — |
| [Constronics Inf](https://app.pivotnow.in/stock/CONSTRONIC) | — | ₹57 Cr | — | — |
| [Kabra Drugs](https://app.pivotnow.in/stock/KABRADG) | — | ₹56 Cr | — | — |

## Questions and answers

### What is the market cap of Samrat Pharma?

Samrat Pharma's market capitalisation is ₹61 Cr (₹61 Cr) at the 22 Oct 2026 close, ranking 2966th among the NSE companies Pivot tracks.

### What is the ROE and ROCE of Samrat Pharma?

Return on equity was 9.9% in FY25 and return on capital employed was 14.7% in FY25 (standalone figures).

### Is Samrat Pharma a debt-free company?

No. Samrat Pharma's debt-to-equity ratio was 0.14 in FY25, with total debt of ₹0 Cr.

### What were Samrat Pharma's latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Samrat Pharma reported revenue of ₹72 Cr, +0.8% year on year, and net profit of −₹2 Cr.

### What is the shareholding pattern of Samrat Pharma?

As of 30 Jun 2026: promoters 49.09%, foreign institutions 3.24%, non-institutions 47.67%.

### Who are Samrat Pharma's competitors?

The listed Pharma & Healthcare companies closest to Samrat Pharma by market cap are Sunil Health, Royal Sense, Bacil Pharma, Veerhealth Care, Constronics Inf and Kabra Drugs.

### Is Samrat Pharma a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Samrat Pharma's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on SAMRATPH against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.